Self important fund manager Neil Woodford flagged up concerns about biotech valuations the other day. Discussing inter alia Plethora (PLE) another bit of a disappointment for my good friend Jim Mellon I look at how investors do and should value such stocks and tend to agree with Woodford that right now risk reward are out of kilter.
on ShareProphets | Comments